The in situ formed ruthenium catalytic system ([Ru]/L) was found to be highly selective for the dehydrogenative coupling reaction of 2-aminophenyl ketones with amines to form quinazoline products. The deaminative coupling reaction of 2-aminobenzamides with amines led to the efficient formation of quinazolinone products. The catalytic coupling method provides an efficient synthesis of quinazoline and quinazolinone derivatives without using any reactive reagents or forming any toxic byproducts. Quinazolines and quinazolinones are a privileged class of nitrogen heterocyclic scaffolds that have been found to exhibit a broad spectrum of pharmacological activities, including anti-inflammatory, antitubercular, and antiviral activities.(1) A number of quinazoline-based drugs such as prazocin and doxazosine have been approved to treat benign prostatic hyperplasia and post-traumatic stress disorder,(2) while both erlotinib and gefitinib have been used for the treatment of lung and pancreatic cancers (Figure 1).(3) Lapatinib, as an inhibitor for epidermal growth factor, has been shown to be effective in combination therapy for breast cancer.(4) Several quinazolinone-based drugs including idelalisib and fenquizone have been shown to exhibit a broad spectrum of antimicrobial, antitumor, antifungal, and cytotoxic activities.(5)